ストックスクリーナーアプリを入手
13.97
0.78%
-0.11
Viatris Inc (VTRS) 最新ニュース
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Viatris Collaborates With GoodRx for Discounts of Up to 85% on Medications - marketscreener.com
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
Trading Systems Reacting to (VTRS) Volatility - Stock Traders Daily
Propranolol Market Overall Study Report 2026-2033 | Teva - openPR.com
Viatris Stock Analysis: Strong 6-Month Gains vs. Poor 5-Year FundamentalsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
Viatris Inc. (VTRS) provides updates on four recent regulatory milestones - MSN
Viatris Eyes Specialty Shift As FDA Reviews MR-141 Presbyopia Drug - Yahoo Finance
Viatris tops forecasts as earnings and revenue beat expectations - MSN
Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating - marketscreener.com
Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis
Ex-Dividend Reminder: Alphabet, Constellation Energy and Viatris - Nasdaq
Viatris Stock Hits Day Low of $15.14 Amid Price Pressure - Markets Mojo
FDA Review Of MR-141 Puts Viatris Ophthalmic Growth Story In Focus - simplywall.st
Viatris, Inc. Hits New 52-Week High at USD 16.46 - Markets Mojo
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360
Generic Pharma Q4 2025 Earnings Review: Revenue Beat, Stock DeclineNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive - FinancialContent
VTRS Financials: Income Statement, Balance Sheet & Cash Flow | Viatris Inc Ord Shs - Stock Titan
A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review - simplywall.st
Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Finviz
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz
Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks
UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey
Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Finviz
JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com
A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update - Yahoo Finance
Viatris (VTRS) Quarterly Loss Of US$340.1 Million Tests Profitability Turnaround Narrative - Sahm
Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus
Viatris Earnings: Drugmaker Left 2025 With Momentum; 2026 to Bring Stability and Broad-Based Growth - Morningstar
Viatris: Q4 Earnings Snapshot - theheraldreview.com
BofA raises Viatris stock price target on cost-cutting plan - Investing.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st
Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Finviz
Earnings call transcript: Viatris Q4 2025 earnings beat forecasts, stock up - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan By Investing.com - Investing.com South Africa
Restructuring: Viatris to cut global workforce by about 10% - Pittsburgh Post-Gazette
Viatris Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 - The Globe and Mail
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy - FinancialContent
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Viatris Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Viatris Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-02-26 - Seeking Alpha
Viatris forecasts 2026 profit below estimates on India manufacturing woes - marketscreener.com
Viatris Launches Major Restructuring After Strong 2025 Results - TipRanks
Viatris maintains annual dividend at 48 cents for 2026 - Investing.com
Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2026 - marketscreener.com
0.25%
0.21%
大文字化:
|
ボリューム (24 時間):